JLL Partners (JLL), the middle-market private equity firm, and Royal DSM (Euronext: DSM KON), the global Life Sciences and Materials Sciences company, today announced the successful closing of the transaction announced in November 2013 combining DSM Pharmaceutical Products (DPP) and Patheon Inc. into a new privately held company, named DPx Holdings B.V. (DPx). As of today, DPx, a leading global contract development and manufacturing organization (CDMO) for the pharmaceutical industry with anticipated sales of around USD 2 billion (pro-forma), a strong EBITDA and operational cash flow and more than 8,000 employees, will become operational. DPx is 51% owned by JLL and 49% by Royal DSM. With he

This article is written by David Carey, and was originally published at http://www.bloomberg.com/news/2014-03-11/jll-s-two-deals-cap-1-7-billion-payback-over-15-months.html. JLL Partners Inc., a 26-year-old private-equity firm based in New York, boosted the cash it has returned to fund investors since the start of last year to $1.7 billion by wrapping up two deals in as many days, according to William Miles, the head of investor relations. JLL garnered $731 million when drug producer Patheon Inc. completed a merger today with vitamin maker Royal DSM NV (DSM)’s drug business. Yesterday, the firm recouped almost half its $85 million investment in BioClinica Inc. when the clinical researcher wa

Durham, N.C. — (March 11, 2014)—DPx Holdings B.V. (DPx), privately owned by JLL Partners and Royal DSM, today launched as a leading global contract development and manufacturing organization (CDMO) for the pharmaceutical and related industries. DPx is the result of a USD $2.65 billion transaction between JLL Partners, a leading middle-market private equity firm, and Royal DSM, the global Life Sciences and Materials Sciences company. DPx is 51 percent owned by JLL Partners and 49 percent by Royal DSM. With headquarters in Durham, N.C., DPx’s global footprint includes 24 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. Formerly known by its pr

CHICAGO and NEW YORK – March 12, 2014 – Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, and JLL Partners, a leading middle-market private equity firm, announced today that they have merged their companies CCBR-SYNARC and BioClinica, Inc. The combination creates a leading global provider of specialty outsourced clinical services. JLL Partners and Water Street invested in BioClinica and CCBR-SYNARC in 2013 and reached an agreement earlier this year to combine the two companies. The firms recruited Jeffrey McMullen, an executive with 40 years of experience in the drug development industry, to serve as chairman. Together, BioClinica and CCB